Is STOK or SVRA more undervalued in 2026?

CirclFi compares Stoke Therapeutics, Inc. (STOK) and Savara, Inc. (SVRA) using 13 institutional-grade valuation models. STOK has a Quality of Company score of 6.2/10 while SVRA scores 4.5/10.

Which is a better buy — STOK or SVRA?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do STOK and SVRA valuations compare?

STOK at $31.61 and SVRA at $5.09 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

STOK vs SVRA Valuation Comparison 2026 — Intrinsic Value Analysis

STOK

Biotechnology

Stoke Therapeutics, Inc.

Quality

6.2

out of 10

Value Trap

SAFE

Price

$31.61

Last close

Models

13/13

Active

SVRA

Biotechnology

Savara, Inc.

Quality

4.5

out of 10

Value Trap

LOW

Price

$5.09

Last close

Models

7/13

Active

Model-by-Model Comparison

Model	Type	STOK Fair Value	STOK Upside	SVRA Fair Value	SVRA Upside
Bayesian DCF	Intrinsic	$11.28	-64.3%	$1.41	-72.2%
Earnings Power Value	Intrinsic	$6.33	-81.0%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$1.47	-95.4%	$0.40	-92.2%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for STOK vs SVRA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

STOK vs SVRA — Which Stock Is More Undervalued?

STOK scores higher with a 6.2/10 quality rating vs SVRA's 4.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Stoke Therapeutics, Inc. (STOK) and Savara, Inc. (SVRA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

STOK currently trades at $31.61 with a QOC of 6.2/10, while SVRA trades at $5.09 with a QOC of 4.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).